Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 51Endometrial Neoplasms 21Fallopian Tube Neoplasms 17Sarcoma 9Peritoneal Neoplasms 9Neoplasm Metastasis 7Neoplasms 6Liposarcoma 6Leiomyosarcoma 5Hemangiosarcoma 5Fibrosarcoma 5Carcinoma, Ovarian Epithelial 5Uterine Neoplasms 4Stomach Neoplasms 4Sarcoma, Synovial 4Recurrence 4Neurofibrosarcoma 4Malignant mesenchymal tumor 4Histiocytoma, Malignant Fibrous 4Desmoplastic Small Round Cell Tumor 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma, Endometrial Stromal 3Rhabdomyosarcoma 3Hemangiopericytoma, Malignant 3Breast Neoplasms 3Appendiceal Neoplasms 3Sarcoma, Alveolar Soft Part 2Pheochromocytoma 2

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2niraparib 1copanlisib 1Standard of Care 1Saline Solution 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Lidocaine 1Gemcitabine 1Conservative Treatment 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease Progression × Doxorubicin × Gynecologic × Clear all
NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

AGC Biologics S.p.A.

Phase 2 Completed
14 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT01358071 2018-09-27

NGR018

AGC Biologics S.p.A.

Phase 2 Completed
119 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡